Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients

Dhikav, Vikas; Singh, Pritika; Anand, Kuljeet Singh

doi:10.1017/s1041610213000744

Cited by 17 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15][16] Previous reports have demonstrated that ignorance about the importance of treatment, the lack of awareness, and previous occurrence of medication nonadherence, all contributed to poor medication adherence. 17,18 The higher rate of discontinuation in our study shows similar reasons. Our survey indicates that misunderstandings about the efficacy of antidementia treatment is one of common reasons that patients withdraw from treatment, including lack of efficacy, treatment refusal and lack of awareness.…”

Section: Discussionsupporting

confidence: 78%

“…Patients with a high level of education are more likely to adhere to medication regimens Previously, Dhikav et al found that illiteracy and lower education levels were primary factors contributing to poor drug adherence. 17 In another study, having more years of formal education decreased the risk of treatment discontinuation in patients with dementia. 19 In our study, patients with higher education levels adhered to their drug treatments longer than patients with lower education levels.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China

Yang

et al. 2020

Psychogeriatrics

View full text Add to dashboard Cite

Background: To investigate the use and adherence of antidementia drugs in elderly patients with dementia from the Memory Clinic of The First Affiliated Hospital of Chongqing Medical University. Methods: Patients were recruited from the Memory Clinic of The First Affiliated Hospital of Chongqing Medical University from December 2010 to December 2018. Medical charts were reviewed, including diagnosis, dosage of antidementia medicines, neuropsychological testing scores, and the further questionnaires were conducted via face-to-face or telephone, included duration of treatment, types of antidementia drugs, and reasons for treatment discontinuation. Results: The data from 422 patients were analysed retrospectively for this study. Three hundred and fifteen were diagnosed with Alzheimer's disease (AD), 67 with mild cognitive impairment (MCI), and 40 with other types of dementia. From the 422 patients, 26.8% were treated with original donepezil (n = 113), 11.6% with generic donepezil (n = 49), 24.6% with memantine (n = 104), 13.3% with huperzine A (n = 56), and 23.7% with a combination of drugs (n = 100). However, 73% of patients discontinued treatment within 1 year of initiation. Patients treated for more than 36 months (37.8%) were more likely to choose combined medication, as compared with patients treated for less than 36 months. Patients with less than 9 years of education (odds ratio (OR): 2.394; 95% CI: 1.508-3.801) were more likely to discontinue treatment than patients with more than 9 years of education. Patients with elevated physical self-maintenance scale (PSMS) scores (OR: 1.195; 95% CI: 1.086-1.316) had a high risk of discontinuation. Conclusions: Overall treatment compliance is relatively poor in memory clinics in Chongqing. Our study demonstrates that higher education may lead to better treatment adherence in dementia care. Combination therapy may increase treatment time. However, poorer PSMS scores are a significant risk factor for treatment discontinuation.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 96%

Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China

Yang

et al. 2020

Psychogeriatrics

View full text Add to dashboard Cite

show abstract

“…In this predominantly elderly group with impaired cognition, compliance is often poor and the potential for misdosage high. Forty-one per cent of patients with AD on cardiovascular drugs were not taking their drugs regularly [52]. Furthermore, although widely used, drugs to treat VRF are not uncommonly associated with side effects, particularly in the elderly population most affected by AD, which can reduce quality of life.…”

Section: Discussionmentioning

confidence: 99%

Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review

Valenti

Pantoni

Markus

2014

BMC Med

View full text Add to dashboard Cite

BackgroundIncreasing evidence suggests vascular risk factors (VRF) play a role in the pathogenesis of Alzheimer’s disease (AD). Epidemiological studies have found associations between VRF and risk of AD. Treating VRF in patients with AD offers a potential treatment option but ineffective treatments should be avoided in this group who are frequently on multiple medications and in whom compliance may be challenging.MethodsStudies containing information on the treatment of VRF in patients with a diagnosis of AD were identified using a defined search strategy. Randomised controlled trials and observational studies were included.ResultsThe pre-specified search strategy retrieved 11,992 abstract articles, and 25 papers including those identified on review of reference lists and reviews met the inclusion criteria. Of these, 11 were randomised controlled trials (RCTs) and 14 observational studies. Observational studies suggested that a VRF package and treatment of hypertension and statin therapy may be associated with improved outcome but these studies suffered from potential bias. The few RCTs performed were mostly small with short duration follow-up, and do not provide clear evidence either way.ConclusionsObservational data raises the possibility that treating VRF could alter the rate of decline in AD. However RCT data are not yet available to support this hypothesis and to alter clinical practice. RCTs in larger numbers of individuals with longer follow-up, ideally in the early stages of AD, are required to address this potentially important treatment question.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-014-0160-z) contains supplementary material, which is available to authorized users.

show abstract

“…It is therefore likely that, for the current study, the cognitively healthier persons in the nutritionally frail population were selected, and this can be seen as a certain selection bias. Consequently, the results should not be generalized to cognitively impaired persons, who most likely face issues relating to unintentional non-compliance, for example by simply forgetting to consume their medications and ONS prescriptions (Dhikav, Singh, & Anand, 2013). Their compliance might therefore rely less on person factors and values, and more on attributes such as a good taste, small volume, or facilitation of ONS by their caregiver.…”

Section: Discussionmentioning

confidence: 99%

That's why I take my ONS. Means-end chain as a novel approach to elucidate the personally relevant factors driving ONS consumption in nutritionally frail elderly users

et al. 2015

View full text Add to dashboard Cite

Medication adherence survey of drugs useful in prevention of dementia of Alzheimer's type among Indian patients

Abstract: Compliance to drugs that have potential or real ability to slow down cognitive decline is low in elderly people with DAT.

Cited by 17 publications

References 18 publications

Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China

Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China

Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review

That's why I take my ONS. Means-end chain as a novel approach to elucidate the personally relevant factors driving ONS consumption in nutritionally frail elderly users

Contact Info

Product

Resources

About